-
Mashup Score: 10
CHICAGO — A once-weekly basal insulin conferred similar HbA1c to once-daily insulins among adults with type 2 diabetes, both in previous basal insulin users and first-time insulin users, according to data from the QWINT trials. At the American Diabetes Association Scientific Sessions, researchers presented findings from the QWINT-1, QWINT-3 and QWINT-4 trials, which assessed once-weekly
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1Swapping diet drinks for water linked to greater weight loss, diabetes remission in women - 15 day(s) ago
CHICAGO — Women who replaced their lunchtime diet beverage with water had greater weight loss and achieved diabetes remission compared with women who continued drinking diet beverages, according to new research. Hamid R. Farshchi, MD, PhD, CEO of D2Type and former associate professor at the University of Nottingham School of Life Sciences, U.K., presented a randomized study at the
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💧Drinking water could be beneficial for your health. Data presented at #ADA2025 showed women who switched from a diet beverage to water lost more weight and were more likely to achieve #diabetes remission. @UoNLifeSci @ADA_DiabetesPro @GoHealio https://t.co/EYD1CMmt5p
-
-
Mashup Score: 2Intervention eliminates population weight gain, prompts patients to seek care for weight - 16 day(s) ago
CHICAGO — An intervention designed to emphasize management of overweight and obesity in primary care settings was associated with population-wide weight loss, researchers reported at the American Diabetes Association Scientific Sessions. The PATHWEIGH intervention was implemented across Colorado at institutions whose primary care practices bought into the process, Leigh Perreault, MD,
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🏥 An intervention centered on #obesity management in primary care clinics led to a greater reduction in body weight than usual care. Dr. Leigh Perreault of @CUAnschutz shares some insights at #ADA2025. @ADA_DiabetesPro https://t.co/38t3zPl25M
-
-
Mashup Score: 3Inhaled insulin safe, effective for children with diabetes - 16 day(s) ago
CHICAGO — Inhaled insulin is an “important alternative” to injected rapid-acting analog insulin for children and teens with diabetes, according to a speaker at the American Diabetes Association Scientific Sessions. Healio previously reported data from the INHALE-3 trial that demonstrated technosphere insulin (Afrezza, MannKind Pharma), a rapid-acting human insulin
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💡Could inhaled #insulin be a therapeutic option for children with #diabetes? Data from INHALE-1 presented at #ADA2025 today showed technosphere insulin conferred similar HbA1c reductions as a rapid-acting analog in kids and teens. @HallerMichael https://t.co/wvl3fSUH50
-
-
Mashup Score: 0
CHICAGO — Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and sustained reductions in body weight compared with placebo, according to data from the phase 3 SLIMMER study.Ecnoglutide (Sciwind Biosciences) had a favorable safety profile and improved other key cardiometabolic risk factors, while also reducing liver fat
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💉A once-weekly novel #GLP1 conferred weight loss of up to 13.2% with a 2.4 mg dose for adults with overweight or #obesity. Learn more about ecnoglutide here: https://t.co/rGyqeNVZwT #ADA2025 @ADA_DiabetesPro #ADASciSessions
-
-
Mashup Score: 1
CHICAGO — The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without diabetes, researchers reported. Results of the REDEFINE 1 trial comparing cagrilintide/semaglutide (CagriSema, Novo Nordisk) with placebo in patients with overweight or obesity and
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📰 Once-weekly combination cagrilintide and semaglutide induced significant weight loss for adults with #obesity. Learn more about the REDEFINE trials presented at #ADA2025 ⬇️ @ADADiabetesPro #ADASciSessions @GoHealio https://t.co/onzY9WmDpe
-
-
Mashup Score: 7
CHICAGO — Orforglipron, a novel nonpeptide, small molecule oral GLP-1, reduced HbA1c at 40 weeks for patients with type 2 diabetes, according to results of the phase 3 ACHIEVE-1 trial. ACHIEVE-1 was presented at the American Diabetes Association Scientific Sessions and simultaneously published in The New England Journal of Medicine. Julio Rosenstock, MD, FACE, senior scientific advisor for
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💊 An oral #GLP1 was tied to significant reductions in HbA1c and body weight for adults with type 2 #diabetes in the ACHIEVE-1 trial. Learn more about orforglipron ⬇️ #ADA2025 @ADA_DiabetesPro #ADASciSessions https://t.co/zVeOkPehgJ
-
-
Mashup Score: 2Screening, treatment of hypercortisolism essential with cardio-renal-metabolic diseases - 16 day(s) ago
PHILADELPHIA — Hypercortisolism is tied to multiple cardio-renal-metabolic disorders, making cortisol level screening an important part of patient monitoring, according to speakers at the Heart in Diabetes CME Conference. The interplay between hypercortisolism and cardio-renal-metabolic disorders was the centerpiece of three talks at the meeting. The presentations examined how
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🎤 “Hypercortisolism’s effect on the kidney, which is very important, causes kidney dysfunction.” @nephonline associate editor Lance Sloan, MD, speaks about how cortisol affects kidney health 👇 #HiD25 @HeartinDiabetes @YHandelsmanMD @CardiologyToday https://t.co/JN3OdWW3Wz
-
-
Mashup Score: 9Weight loss with tirzepatide sustained for more than 3 years - 16 day(s) ago
CHICAGO — In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according to new data from the SURMOUNT-1 study. As Healio previously reported, in the main SURMOUNT-1 study, nearly all participants assigned tirzepatide (Zepbound, Eli Lilly) experienced at least 5% weight loss over 72 weeks compared with placebo — more
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🏥 Adults with #obesity and prediabetes receiving #tirzepatide in SURMOUNT-1 maintained their weight loss for more than 3 years. Hear from @drard about this data presented at #ADASciSessions 👇 #ADA2025 @ADA_DiabetesPro https://t.co/kTXgFG87mL
-
-
Mashup Score: 7Benefits of Ozempic in peripheral artery disease consistent across spectrum of diabetes - 16 day(s) ago
CHICAGO — Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless of baseline diabetes duration, HbA1c, BMI and concomitant medication use. Subodh Verma, MD, PhD, FRCSC, professor of medicine, cardiac surgeon and the Canada Research Chair in Cardiovascular Surgery at University of Toronto, presented new insights from
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🚶Walking distance improved for adults with early peripheral artery disease plus type 2 #diabetes, regardless of characteristics such as HbA1c, BMI and medication use at baseline. @ADA_DiabetesPro #ADA2025 #ADASciSessions @CardiologyToday @SubodhVermaMD https://t.co/T62knMv6UP
-
🚨Presented today at #ADA2025: Data from three QWINT trials showed once-weekly insulin efsitora provided similar HbA1c reductions as once-daily basal insulins in adults with type 2 #diabetes. @athenatsimikas @ADA_DiabetesPro #ADASciSessions @GoHealio https://t.co/pvL1EOoAly